ARE offers an asymmetric recovery opportunity as a dominant life science landlord trades at distressed multiples, but leverage and disposition execution make stabilization the critical investment test.
Overview
Alexandria Real Estate Equities is the leading owner, operator, and developer of life science megacampuses in high-barrier North American innovation clusters. Its portfolio benefits from mission-critical laboratory infrastructure, long-duration leases, contractual escalators, and tenants including Eli Lilly, Bristol Myers Squibb, Novartis, Roche, Alphabet, Moderna, and Illumina. The top 20 tenants contribute 36.4% of annual rental revenue, while Moderna is the largest tenant at 5.8%. **The operating picture is currently transitional:** 2Q26 revenue fell 13.0% year over year to $662.78 million, adjusted FFO per share declined 25.8% to $1.73, operating occupancy fell to 86.9%, and GAAP same-property NOI declined 10.6%. However, leasing volume increased 60% sequentially to 1,038,917 RSF, renewal spreads improved materially, and adjusted occupancy including signed future leases was 90.9%. Valuation is deeply discounted at 7.8x–8.3x forward FFO versus an 18.4x 10-year average, 0.46x book value, and a 5.7% forward dividend yield after the 45% dividend cut. Near-term catalysts include asset-sale execution, delivery of 1.4 million RSF of signed leases, biotech funding recovery, and credit-line amendments.